Vis enkel innførsel

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

dc.contributor.authorMoorkens, Evelien
dc.contributor.authorGodman, Brian
dc.contributor.authorHuys, Isabelle
dc.contributor.authorHoxha, Iris
dc.contributor.authorMalaj, Admir
dc.contributor.authorKeuerleber, Simon
dc.contributor.authorStockinger, Silvia
dc.contributor.authorMörtenhuber, Sarah
dc.contributor.authorDimitrova, Maria
dc.contributor.authorTachkov, Konstantin
dc.contributor.authorVončina, Luka
dc.contributor.authorPalčevski, Vera Vlahović
dc.contributor.authorAchniotou, Gnosia
dc.contributor.authorSlabý, Juraj
dc.contributor.authorPopelková, Leona
dc.contributor.authorKohoutová, Kateřina
dc.contributor.authorBartels, Dorthe
dc.contributor.authorLaius, Ott
dc.contributor.authorMartikainen, Jaana E.
dc.contributor.authorSelke, Gisbert
dc.contributor.authorKourafalos, Vasileios
dc.contributor.authorMagnusson, Einar
dc.contributor.authorEinarsdóttir, Rannveig
dc.contributor.authorAdams, Roisín
dc.contributor.authorJoppi, Roberta
dc.contributor.authorAllocati, Eleonora
dc.contributor.authorJakupi, Arianit
dc.contributor.authorViksna, Anita
dc.contributor.authorGreičiūtė-Kuprijanov, Ieva
dc.contributor.authorVella Bonanno, Patricia
dc.contributor.authorSuttorp, Vincent
dc.contributor.authorMelien, Øyvind
dc.contributor.authorPlisko, Robert
dc.contributor.authorMardare, Ileana
dc.contributor.authorMeshkov, Dmitry
dc.contributor.authorNovakovic, Tanja
dc.contributor.authorFürst, Jurij
dc.contributor.authorZara, Corrine
dc.contributor.authorMarkovic-Pekovic, Vanda
dc.contributor.authorGrubiša, Nataša
dc.contributor.authorBefrits, Gustaf
dc.contributor.authorPuckett, Robert
dc.contributor.authorVulto, Arnold G.
dc.date.accessioned2021-03-18T12:21:03Z
dc.date.available2021-03-18T12:21:03Z
dc.date.created2021-02-12T13:20:00Z
dc.date.issued2021
dc.identifier.citationFrontiers in Pharmacology. 2021, 11 .
dc.identifier.issn1663-9812
dc.identifier.urihttps://hdl.handle.net/11250/2734213
dc.language.isoeng
dc.titleThe Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersion
dc.source.pagenumber17
dc.source.volume11
dc.source.journalFrontiers in Pharmacology
dc.identifier.doi10.3389/fphar.2020.591134
dc.identifier.cristin1889191
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail
Filnavn:
Moorkens_2021_The.pdf
Størrelse:
1.022Mb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel